MedImmune

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
MedImmune, LLC
Subsidiary
Industry Pharmaceutical
Founded 1988; 30 years ago (1988) (as Molecular Vaccines, Inc.)
1989; 29 years ago (1989) (as MedImmune, Inc.)
Headquarters Gaithersburg, Maryland, U.S.
Products Synagis
FluMist
Parent AstraZeneca
Website www.medimmune.com

MedImmune, LLC is a wholly owned subsidiary of AstraZeneca. MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion.[1] It currently has locations in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA.[2]

It produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune acquired FluMist when it purchased Aviron in 2002 for US$ 1.5 billion. FluMist sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006.[3]

FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market—young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store.[4]

MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was approved by the U.S. Food and Drug Administration (FDA) in 2007, and is now the form offered on the market.

History[edit]

Molecular Vaccines, Inc. was founded by Wayne T. Hockmeyer in 1988.[4] In 1989, Molecular Vaccines, Inc changed its name to MedImmune, Inc.

On April 23, 2007, it was announced MedImmune and AstraZeneca entered into a definitive agreement under which AstraZeneca intended to acquire MedImmune in an all-cash transaction at US$ 58 per share, or about US$ 15.2 billion.[4] On 19 June 2007 AstraZeneca completed the acquisition paying US$ 15.2 billion primarily for its drug development pipeline. Analysts have criticised the take-over, claiming that AstraZeneca paid too much.[5] AstraZeneca chose to merge MedImmune with Cambridge Antibody Technology, which it had acquired in 2006, creating a new biologics division under the MedImmune name. AstraZeneca presented the new MedImmune to investors on 7 December 2007.[6]

In June 2007, the National Institutes of Health (NIH) began enrolling participants in a Phase 1 H5N1 study of an intranasal influenza vaccine candidate based on MedImmune's live, attenuated vaccine technology.[7]

MedImmune said it was making a significant, rapid response with a vaccine to the novel H1N1 variant of influenza, known as swine flu.[8] In June 2009 it won a Department of Health and Human Services (HHS) contract, worth $90m. Under the contract with HHS, MedImmune will continue to make its seasonal FluMist vaccine and also develop a vaccine targeted specifically at the novel H1N1 virus.[3] MedImmune then won a second contract to test its nasal spray flu technology as a viable treatment for the H1N1.[9]

MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine in September 2009.[8]

Pipeline[edit]

MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer. Major phase III trials include:[10]

See also[edit]

Sources and notes[edit]

  1. ^ https://www.nytimes.com/2007/04/24/business/24drug-web.html?mcubz=3
  2. ^ https://www.medimmune.com/about-us.html
  3. ^ a b Michael S. Rosenwald (June 2, 2009). "MedImmune Wins Key Contract To Develop Swine Flu Vaccine". The Washington Post. Retrieved October 23, 2009. 
  4. ^ a b c
  5. ^ AstraZeneca's big, risky $15 billion bet
  6. ^ http://www.astrazeneca.com/media/latest-press-releases/2007/5364?itemId=3891554
  7. ^ MedImmune Press release MedImmune and National Institutes of Health Begin Clinical Testing of a Live, Attenuated Intranasal Vaccine Against an H5N1 Avian Influenza Virus published June 15, 2007
  8. ^ a b "MedImmune Influenza A (H1N1) Information". Archived from the original on September 24, 2009. Retrieved October 23, 2009. 
  9. ^ Sinha, Vandana (13 July 2009). "MedImmune gets second H1N1 flu contract". 
  10. ^ https://www.medimmune.com/our-science/pipeline.html

External links[edit]